Ind-Swift Laboratories Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	8.3yrs

Recent management updates

Recent updates

CEO

Ind-Swift Laboratories has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Navrattan Munjal	Chairman & MD	29yrs	₹36.15m	1.56% ₹ 115.0m
Himanshu Jain	Joint MD & Whole Time Director	20.8yrs	₹28.93m	0.69% ₹ 50.8m
Rishav Mehta	Executive Director	14.1yrs	₹14.48m	0.77% ₹ 57.2m
Sahil Munjal	President of Operations & Special Assignments and Executive Director	4.2yrs	₹17.39m	0.011% ₹ 845.3k
Sri Sharma	Non-Executive Independent Director	11.6yrs	₹132.50k	no data
Ashwani Vig	Non-Executive Independent Director	4.2yrs	₹92.50k	no data
Neerja Chathley	Non-Executive Independent Woman Director	4.9yrs	₹65.00k	no data
Rajinder Gupta	Non-Executive Independent Director	2.8yrs	₹95.00k	no data

8.3yrs

Average Tenure

67yo

Average Age

Experienced Board: 532305's board of directors are considered experienced (8.3 years average tenure).

Ind-Swift Laboratories Management

Management criteria checks 1/4

Key information

Recent management updates

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

Group Head of Human Resources recently sold ₹3.3m worth of stock

Chief Accounts Officer recently sold ₹1.6m worth of stock

Insufficient new directors

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.6m worth of stock

Recent updates

Investor sentiment improves as stock rises 16%

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Essix Biosciences Limited.

Third quarter 2024 earnings released: EPS: ₹3.29 (vs ₹4.65 in 3Q 2023)

Ind-Swift Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024

Second quarter 2024 earnings released: EPS: ₹5.36 (vs ₹4.29 in 2Q 2023)

Ind-Swift Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: ₹2.92 (vs ₹3.36 in 1Q 2023)

Ind-Swift Laboratories Limited to Report Q1, 2024 Results on Aug 09, 2023

Group Head of Human Resources recently sold ₹3.3m worth of stock

Investor sentiment improves as stock rises 15%

Chief Accounts Officer recently sold ₹1.6m worth of stock

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: ₹4.65 (vs ₹2.71 in 3Q 2022)

Insider recently sold ₹1.2m worth of stock

Second quarter 2023 earnings released: EPS: ₹4.29 (vs ₹4.14 in 2Q 2022)

Insider recently sold ₹1.6m worth of stock

Ind-Swift Laboratories Limited to Report Fiscal Year 2023 Results on May 30, 2023

First quarter 2023 earnings released: EPS: ₹3.36 (vs ₹3.18 in 1Q 2022)

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2022

Ind-Swift Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: ₹0.36 loss per share (vs ₹0.53 loss in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹4.14 (vs ₹1.68 in 2Q 2021)

Investor sentiment deteriorated over the past week

Soft Air General Trading LLC agreed to acquire Ind-Swift Middle East FZ-LLC from Ind-Swift Laboratories Limited (BSE:532305) for approximately $2 million.

First quarter 2022 earnings released: EPS ₹3.18 (vs ₹0.77 in 1Q 2021)

High number of new directors

Full year 2021 earnings released: ₹0.53 loss per share (vs ₹4.28 loss in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insider recently sold ₹1.0m worth of stock

Independent Director has left the company

Insider recently sold ₹1.4m worth of stock

Investor sentiment improved over the past week

New 90-day high: ₹86.75

Insider recently sold ₹2.1m worth of stock

Third quarter 2021 earnings released: EPS ₹1.95 (vs ₹1.90 loss in 3Q 2020)

Ind-Swift Laboratories Limited to Report Q3, 2021 Results on Feb 12, 2021

Investor sentiment deteriorated over the past week

Ind-Swift Labs' Promoters Reportedly Sound Out PEs to Sell Their Stake

Senior Vice President of Procurement recently sold ₹2.7m worth of stock

Investor sentiment improved over the past week

New 90-day high: ₹70.80

Insider recently sold ₹1.2m worth of stock

Senior Vice President of QA recently sold ₹1.4m worth of stock

Market bids up stock over the past week

New 90-day high: ₹59.15

Second quarter 2021 earnings released: EPS ₹1.68

New 90-day high: ₹58.90

New 90-day high: ₹41.30

New 90-day high - ₹40.20

Ind-Swift Laboratories Limited to Report Q1, 2021 Results on Jul 25, 2020

CEO

Board Members

Average Tenure

Average Age